2-(2-(naphthalen-1-yloxy)ethyl)isoindoline-1,3-dione | 118868-72-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(2-(naphthalen-1-yloxy)ethyl)isoindoline-1,3-dione
• 英文别名: N-(2-(1-naphthyloxy)ethyl)phthalimide；N-[2-(1-naphthyloxy)ethyl]phthalimide；2-(2-naphthalen-1-yloxyethyl)isoindole-1,3-dione
• CAS: 118868-72-7
• 化学式: C₂₀H₁₅NO₃
• 分子量: 317.344
• InChiKey: VCTQSNZPKYVLNJ-UHFFFAOYSA-N

物化性质

• 熔点：
  126-128 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• 沸点：
  516.4±33.0 °C(Predicted)
• 密度：
  1.307±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-(naphthalen-1-yloxy)ethyl)isoindoline-1,3-dione 以64%的产率得到
  参考文献：
  名称：

  PIERSON, M. EDWARD;LYON, ROBERT A.;TITELER, MILT;KOWALSKI, PAUL;GLENNON, +, J. MED. CHEM., 32,(1989) N, C. 859-863

  摘要：

  DOI：
• 作为产物：
  描述：

  萘酚 在 偶氮二甲酸二异丙酯 、 potassium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 2-(2-(naphthalen-1-yloxy)ethyl)isoindoline-1,3-dione
  参考文献：
  名称：

  [EN] IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C
  [FR] INHIBITEURS COVALENTS IRRÉVERSIBLES DE LA GTPASE K-RAS G12C

  摘要：

  提供了包含G12C突变的K-Ras、H-Ras或N-ras蛋白的不可逆抑制剂。还公开了调节包含G12C突变的K-Ras、H-Ras或N-ras蛋白活性的方法，以及调节由K-Ras、H-Ras或N-ras G12C介导的疾病的方法。

  公开号：

  WO2014143659A1

文献信息

• Chiral Aryloxyalkylamines: Selective 5-HT1B/1D Activation and Analgesic Activity
  作者：Alessia Carocci、Giovanni Lentini、Alessia Catalano、Maria Maddalena Cavalluzzi、Claudio Bruno、Marilena Muraglia、Nicola Antonio Colabufo、Nicoletta Galeotti、Filomena Corbo、Rosanna Matucci、Carla Ghelardini、Carlo Franchini

  DOI：10.1002/cmdc.200900530

  日期：2010.5.3

  A series of chiral 2,3‐dichlorophenoxy and 1‐naphthyloxy alkylamines were synthesized, and their binding affinities towards 5‐HT1D and h5‐HT1B receptors were evaluated. In the naphthyloxy series, the (R)‐prolinol derivative was the most selective 5‐HT1D ligand, while (S)‐N‐methyl‐2‐(1‐naphthyloxy)propan‐1‐amine showed the highest selectivity for h5‐HT1B. Both compounds performed as 5‐HT1D agonists

  合成了一系列手性2,3-二氯苯氧基和1-萘氧基烷基胺，并评估了它们对5-HT 1D和h5-HT 1B受体的结合亲和力。在萘氧基系列中，（ R ）-脯氨醇衍生物是选择性最高的5-HT 1D配体，而（ S ） -N-甲基-2-（1-萘氧基）丙-1-胺对h5-的选择性最高HT 1B。两种化合物在分离的豚鼠试验中均作为5‐HT 1D激动剂发挥作用，并且显示出比舒马曲坦和非手性类似物20  b更高的镇痛活性。在鼠标热板测试中。两种配体都没有对小鼠脑膜中存在的烟碱型ACh受体表现出任何亲和力，因此表明它们的镇痛活性不会通过与这些受体的相互作用而产生。
• IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：US20160031898A1

  公开（公告）日：2016-02-04

  Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediated by K-Ras, H-Ras or N-ras G12C.

  提供了包含G12C突变的K-Ras、H-Ras或N-ras蛋白的不可逆抑制剂。还公开了调节包含G12C突变的K-Ras、H-Ras或N-ras蛋白活性的方法，以及治疗由K-Ras、H-Ras或N-ras G12C介导的疾病的方法。
• Design and synthesis of propranolol analogs as serotonergic agents
  作者：M. Edward Pierson、Robert A. Lyon、Milt Titeler、Paul Kowalski、Richard A. Glennon

  DOI：10.1021/jm00124a021

  日期：1989.4

  Serotonin (5-HT) binds with nearly identical affinity at the various central 5-HT binding sites. Few agents bind with selectivity for 5-HT1A sites. The beta-adrenergic antagonist propranolol binds stereoselectively both at 5-HT1A and 5-HT1B sites (with a several-fold selectivity for the latter) and, whereas it is a 5-HT1A antagonist, it appears to be a 5-HT1B agonist. As such, it could serve as a lead compound for the development of new 5-HT1A and 5-HT1B agents. The purpose of the present study was to modify the structure of propranolol in such a manner so as to reduce its affinity for 5-HT1B and beta-adrenergic sites while, at the same time, retaining its affinity for 5-HT1A sites. Removal of the side-chain hydroxyl group of propranolol, and conversion of its secondary amine to a tertiary amine, reduced affinity for 5-HT1B and beta-adrenergic sites. In addition, shortening the side chain by one carbon atom resulted in compounds with affinity for hippocampal 5-HT1A sites comparable to that of racemic propranolol, but with a 30- to 500-fold lower affinity for 5-HT1B sites and a greater than 1000-fold lower affinity for beta-adrenergic sites. The results of these preliminary studies attest to the utility of this approach for the development of novel serotonergic agents.
• US9745319B2
  申请人：——

  公开号：US9745319B2

  公开（公告）日：2017-08-29